NeoGenomics posted a $45 million net loss in the second quarter of 2025, a 142% increase from the same period last year, driven by $20 million in impairment charges. Despite the loss, the Fort Myers-based cancer diagnostics company reported record quarterly revenue of $181 million, up 10% year over year. Clinical revenue rose 16%, fueled by higher test volumes and growth in next-generation sequencing services, company officials said. The company completed its acquisition of Pathline in April and reaffirmed its full-year guidance of up to 10% revenue growth. Adjusted EBITDA held steady at $10.7 million. CEO Tony Zook said upcoming product launches, including the PanTracer Liquid Biopsy test and expanded research and development efforts position NeoGenomics for future growth. The company ended the quarter with $164 million in cash and marketable securities.